Drugs / BT-KTM-I
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06092684 | Sep 2023 → Mar 2024 | — | Chengdu Brilliant Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT-KTM-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06092684 ↗ |